The BODE Index is a validated prognostic tool for chronic obstructive pulmonary disease (COPD), combining four independent domains — Body-mass index, airflow Obstruction, Dyspnea, and Exercise capacity — into a single 0-10 point score. Derived by Celli and colleagues (NEJM 2004), it predicts multi-year survival more accurately than FEV1 alone, because it captures the systemic, functional, and symptomatic burden of COPD rather than just lung mechanics.

How the BODE Index works

The BODE Index sums four tiered domain scores. BMI is scored on a simple 2-tier scale (0 or 1 point) at a threshold of 21 — patients with a BMI at or below 21 had worse survival in the derivation cohort. FEV1 % predicted, the mMRC dyspnea scale, and 6-minute walk distance are each scored on 4-tier scales (0 to 3 points), where more severe airflow obstruction, more severe breathlessness, and shorter walk distance each add more points. The total ranges from 0 (best prognosis) to 10 (worst prognosis).

The four domains were chosen because each independently predicted mortality in COPD, and combining them produced better discrimination than any single measure — notably outperforming FEV1 alone, which captures airflow limitation but not the systemic muscle wasting, breathlessness, or functional decline that also drive COPD mortality.

Reading the quartiles

The BODE Index derivation cohort was divided into four score-range quartiles, each with a published 4-year survival rate: Quartile 1 (0-2 points) at approximately 80%, Quartile 2 (3-4 points) at approximately 67%, Quartile 3 (5-6 points) at approximately 57%, and Quartile 4 (7-10 points) at approximately 18%. Survival drops sharply between quartiles 3 and 4, making a score of 7 or higher a meaningful threshold for discussing advanced COPD management, pulmonary rehabilitation, and goals-of-care planning.

Limits and how it should be used

The BODE Index is a population-derived prognostic estimate, not a certainty for any individual patient — it does not account for comorbidities, exacerbation frequency, or treatment response, all of which also influence COPD outcomes. It was derived in a specific patient cohort and should be interpreted alongside, not instead of, a full clinical assessment. This calculator is for education and clinical decision support only; prognosis discussions and treatment decisions should always involve the treating clinician's complete evaluation of the patient.